Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 8;18(2):159–168. doi: 10.1111/dom.12584

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

DOM-12584-FIG-0004-b — (A) Effect of treatment‐emergent antibody response (TEAR) status on change in clinical outcomes [glycated haemoglobin (HbA1c), basal insulin dose, total hypoglycaemia rate] in the type 1 diabetes (T1DM) full analysis set (FAS) population. (B) Effect of TEAR status on change in clinical outcomes (HbA1c, basal insulin dose, total hypoglycaemia rate) in the type 2 diabetes (T2DM) FAS population. Data are presented as least squares mean ± standard error change from baseline to LOCF endpoint. p > 0.05 for all treatment‐by‐TEAR interactions. IGlar, insulin glargine; LOCF, last‐observation‐carried‐forward (endpoint); LY IGlar, LY2963016 insulin glargine.